Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 18/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 13/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4539171 | 0.95 | MCHR1 (0.71) | MCHR1KCNH2CYP3A4HRH3 | |
| SCHEMBL4532093 | 0.87 | MCHR1 (0.72) | MCHR1KCNH2HRH3 | |
| SCHEMBL4541246 | 0.85 | MCHR1 (0.64) | MCHR1KCNH2CYP3A4HRH3 | |
| SCHEMBL4533285 | 0.85 | MCHR1 (0.54) | MCHR1KCNH2CYP3A4 | |
| SCHEMBL4542346 | 0.84 | MCHR1 (0.56) | MCHR1KCNH2CYP3A4HRH3 | |
| SCHEMBL4541266 | 0.84 | HRH3 (0.46) | MCHR1KCNH2HRH3 | |
| SCHEMBL4526443 | 0.84 | MCHR1 (0.56) | MCHR1KCNH2CYP3A4 | |
| SCHEMBL4534814 | 0.84 | MCHR1 (0.86) | MCHR1KCNH2CYP3A4HRH3 | |
| SCHEMBL4541238 | 0.84 | MCHR1 (0.61) | MCHR1KCNH2CYP3A4HRH3 | |
| SCHEMBL4533275 | 0.83 | MCHR1 (0.61) | MCHR1KCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264426-A1 | Bicyclic aromatic substituted pyridone derivative | MSD K.K. (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090264426-A1 | Bicyclic aromatic substituted pyridone derivative | MSD K.K. (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090264426-A1 | Bicyclic aromatic substituted pyridone derivative | MSD K.K. (JP) | 2009-10-22 | — | — | US | disclosed |
| EP-1939194-A1 | BICYCLIC AROMATIC SUBSTITUTED PYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-1939194-A1 | BICYCLIC AROMATIC SUBSTITUTED PYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264426-A1 | Bicyclic aromatic substituted pyridone derivative | PYCR1, CHRM1, MTR | MCHR1 357/4885KCNH2 975/4885CYP3A4 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.